A sample of the government webpages Trump doesn't want you to see
Catherine Rampell is a Post Opinions columnist; Amanda Shendruk and Flavio Pessoa are Post Opinions graphics reporters.
Not found: That was the resounding message across federal websites this week, as the Trump administration has disappeared thousands of taxpayer-funded websites. Though some pages have been restored, those still missing contain decades' worth of information critical to scientists, physicians, urban planners, businesses and families.
CDC PEPFAR data dashboard
Current / Archive
CEJST Climate and Economic Justice Screening Tool
Current
DHS 2025 Strategic Plan
Current / Archive
DOI Acquisition Sustainability
Current / Archive
DOI Blog post: An Agenda Rooted in Environmental Justice
Current / Archive
EPA EJScreen: Environmental Justice Screening and Mapping Tool
Current / Archive
EPA NCEE Seminar: Efficiency, equity, and cost-recovery tradeoffs in municipal water pricing
Current
FDA Identifying and Measuring Artificial Intelligence (AI) Bias for Enhancing Health Equity
Current / Archive
NGA History (National Geospatial-Intelligence Agency)
Current / Archive
NIH Science Education Partnership Award (SEPA)
Current / Archive
NIST Diversity in the Manufacturing Workforce
Current / Archive
US Marshals Federal Performance-Based Detention Standards
Current / Archive
USDA Climate Change Across USDA
Current / Archive
USDA Climate Change Resource Center
Current / Archive
Some pages have been taken down while the administration scrubs them of references to transgender people, diversity, equity and inclusion, 'gender ideology,' and related wrongthink banned by the president's recent executive orders.
CDC National Intimate Partner and Sexual Violence Survey
Current / Archive
Census Sexual Orientation & Gender Identity (SOGI) Data
Current / Archive
DOD Black History Month
Current / Archive
DOJ Civil Rights Division: LGBTQI+ Working Group
Current / Archive
DOJ Office for Victims of Crime: Responding to transgender victims of sexual assault
Current / Archive
DOJ Working with LGBTQ Communities
Current / Archive
DOT Screening Tool for Equity Analysis of Projects (STEAP)
Current
FDA Minority Health and Health Equity Research and Collaboration
Current / Archive
HHS Protecting the Rights of Lesbian, Gay, Bisexual, Transgender, Queer, and Intersex (LGBTQI+) People
Current / Archive
NCES Fast Facts: LGBTQ+ Pride Month
Current / Archive
NIH Sexual & Gender Minority Research Office
Current / Archive
NIST Zero Tolerance Harassment Policy
Current / Archive
NOAA National Ocean Service Diversity
Current / Archive
NRC Special Emphasis Programs and EEO Advisory Committees
Current / Archive
OJP Grants Aimed at Combatting Rise in Hate Crimes
Current / Archive
OJP Teen Dating Violence
Current / Archive
OPM Diversity and Inclusion FAQ
Current / Archive
SAMHSA Guidance for Improving Staff Engagement: Integrating Diversity, Equity, and Inclusion (DEI) in SOAR Work
Current / Archive
U.S. Army U.S. Army Women's Museum
Current / Archive
USDA Climate Solutions
Current
VA LGBTQ+ Veteran Care
Current / Archive
Others have been deleted or altered for unknown reasons. Here's just a small sample of data series, reports and tax forms that have gone missing:
ATSDR CDC Social Vulnerability Index
Current / Archive
ATSDR Environmental Justice Index 2024 Update
Current / Archive
Census Household Pulse Survey Technical Documentation
Current / Archive
Census Survey of Business Owners (SBO)
Current
FEMA 2022–2026 FEMA Strategic Plan
Current / Archive
IRS Form 5578: Annual Certification of Racial Nondiscrimination for a Private School Exempt From Federal Income Tax
Current / Archive
USAID Entire website
Current / Archive
USPTO Veterans Innovation and Entrepreneurship Program event series
Current / Archive
And here are examples of funding programs and pages offering health advice that are nowhere to be found. As of publication time, they were all inaccessible. It's unclear when they will come back online — if at all.
CDC Health Education Curriculum Analysis Tool (HECAT) Summary Fact Sheet
Current / Archive
CDC CDC clinical practice guideline: PrEP for the prevention of HIV infection in the United States
Current / Archive
FDA Guidance: Evaluation of Sex-Specific Data in Medical Device Clinical Studies
Current
HeadStart Mothers and Babies: An Intervention to Prevent Postpartum Depression
Current / Archive
HeadStart The Importance of Schedules and Routines
Current / Archive
HRSA Supporting Care for Women with Opioid Use Disorder (OUD)
Current / Archive
NASA SERVIR
Current / Archive
NIH Office of Research on Women's Health
Current / Archive
ODNI Semiannual reports from ODNI's Office of the Inspector General
Current / Archive
Story continues below advertisement
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Trump Pushes to Extend Federal Control of Washington Police, Eyes Broader Powers
U.S. President Donald Trump says he'll ask Congress to extend federal control over Washington D.C.'s police force beyond the 30 days allowed under current law — and he believes the move could serve as a model for other cities.
Yahoo
28 minutes ago
- Yahoo
Editorial: Saving lives no more — RFK risks us all in targeting mRNA vaccine research
Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human Services, has announced that he will be rescinding a half billion dollars in grants and contracts for the development of mRNA technology and vaccines. It was mRNA that was key to both the Pfizer-BioNTech and the Moderna COVID vaccines that were created under Trump in his first term, but RFK does not like life-saving vaccines and so he's pulling the plug. Part of the problem with policymaking at the level of the federal government is that the impacts are often too large, too long-winded, too abstract to really be able to nearly encompass their full breadth, particularly for busy people who have their own immediate concerns to worry about. In this case, though, we can point to very clear, very grim and almost unavoidable repercussions directly caused by this decision: many people worldwide — including in the United States — will die deaths that could have been prevented. Setting aside all of the jargon, at its most basic level a vaccine is about allowing the body to ward off or survive pathogens that would otherwise be extremely dangerous and debilitating or kill a person outright. The model itself is far from new; inoculations in some form of another, including the basic utilization of a dead virus to create antibodies that can attack a live one, date back centuries. What's mainly changed since then is that we have only advanced our understanding and technology to keep infectious diseases from running rampant in our society. One such technological leap was the mRNA process, an innovation so significant that its pioneers won the Nobel prize. The effectiveness and the safety of this process has been well-documented in research settings, but we don't even have to parse the studies to know this because we all collectively lived it. As Trump's Operation Warp Speed produced, the first and most widespread COVID inoculations were mRNA-based vaccines, which enabled us to blunt the rampaging pandemic and much more quickly return our society to a semblance of normalcy. Those COVID vaccines have already been synthesized, but the real issue here are the ones that haven't, or even the inoculations for viruses that we have not even identified or think to be a threat today. Whether we like it or not, our relationship to infectious diseases is something akin to an arms race, in which we are constantly trying to counteract pathogens that, by dint of evolution, are constantly finding ways to elude our defenses and sicken us. We've stayed largely on top of this arms race over the last six decades or so in particular because of constant efforts that have developed sophisticated tools to fight back, including mRNA. A disarmament here for no other reason than ideologically-driven conspiracy that drives Bobby Kennedy is going to mean that we give the diseases an opening, which they will no doubt exploit to sicken and kill us. There are quite simply no two ways about it, and any pause in the research could have dire consequences, even if it is reversed later. Ongoing and sometimes multimonth or even multiyear projects will lose funding and might have to be shut down, with all their efforts wasted. There's no way to really put the genie back in the bottle so we have to stop it in the first place, which means RFK must be fired immediately or impeached and removed by Congress. Many lives hang in the balance. _____
CNBC
30 minutes ago
- CNBC
Trump's meeting with Putin is a win-win for European defense stocks, no matter the outcome
European defense stocks have further to run regardless of whether U.S. President Donald Trump and Russian counterpart Vladimir Putin achieve a breakthrough on the war in Ukraine later this week, market watchers say. Trump and Putin are slated to meet in person in Alaska on Friday, with a view to discuss what it would take to end the more-than-three-year conflict that began with Russia's full-scale invasion of Ukraine in early 2022. Reports that the two heads of state would meet buoyed broader European equities on Thursday, but sank regional defense stocks . Concerns about Russian aggression had contributed to decisions by European governments and the NATO military alliance to drastically hike their defense budgets, benefiting security companies operating in the region . So far this year, the Stoxx Europe Aerospace and Defense index has surged by 52%. Following three consecutive days of losses after the Trump-Putin summit was announced, the index regained some ground, and was last seen trading 1.3% higher in Thursday's session. Market watchers told CNBC that a deal to end the fighting in Ukraine — which may not be on the horizon of Friday's meeting — was unlikely to throw Europe's defense growth off course. 'Win-win' for defense stocks In emailed comments to CNBC on Wednesday, Dmitrii Ponomarev, product manager at VanEck EU, pointed to a recent Financial Times report that Europe is "building for war," with arms sites expanding at roughly thrice the pace struck during peace time. He labeled this as "evidence that the current ramp is broader than Ukraine resupply alone." "No firm would add that much capacity if it depended only on Ukraine shipments; the bigger driver is NATO Europe's pivot to modernization and restocking under the new 5% of GDP long-term goal, of which about 3.5% is the truly comparable "core" defense spend, anchoring multi-year demand," he said. "Even with a peace deal, stockpiles don't magically refill: governments still face years of munitions and air-defense replenishment, so revenues likely shift from short-term surge programs toward steadier replenishment, sustainment, and long-horizon modernization." VanEck runs a $6.9 billion Defense ETF, which includes stakes in some of Europe's biggest defense stocks. Among the fund's top holdings are Italy's Leonardo , France's Thales and Sweden's Saab . Ponomarev said that companies that rely more heavily on deliveries to Ukraine or supplying short-cycle munitions "may feel a sharper de-rating if urgency fades" from any potential breakthrough emerging from this week's Alaska summit between the Russian and U.S. leadership. "[But] more diversified primes with long-cycle programs, services, and sustainment should be better placed to absorb near-term volatility," he said. Asked on Monday whether the European defense boom remained a long-term story regardless of the outcome in Ukraine, Christopher Granville, managing director of TS Lombard, said he "strongly agrees" that the momentum has further to run. "My call on European defense stocks since about 2023 — when it became clear that the Russian military was extremely powerful and was not going to be rolled out of those territories in eastern and southern Ukraine — has been buy on any weakness, on any temporary pullback, because this is a win-win for European defense stocks," he told CNBC's "Squawk Box Europe." Granville pointed out that either the negotiations would go off the rails on Friday — an outcome that he labeled "more than perfectly possible, if not likely" — or peace would be struck. The former would result in the need for America and Europe to replenish their arms inventories, he said, while the latter would lead to "a very powerful Russian military." "Although the words victory and defeat [would] be bandied around, [this would be] a Russian military which has to an extent, prevailed," he said. "That reality will force a continued increase in defense procurement by European governments, and it's also good for European defense stocks. Either way, it's a winner." Granville noted that markets had been discounting the second scenario's ability to benefit defense companies. "From time to time, those names pull back a bit — you should buy on that weakness in my opinion," he advised. 'At least a decade' of rearmament Defense company leaders have been telling CNBC in recent weeks that an end to the Ukraine war would be unlikely to derail the boost to European defense spending. In conversation with CNBC's "Worldwide Exchange" on Monday, Dimitrios Kottas, co-founder and CEO of Greek autonomous defense tech developer Delian Alliance Industries, said the timing of Europe's consensus to modernize defense capabilities was correlated with the invasion of Ukraine, but argued that this rearmament would last "at least a decade." "It's something that is driven by historical macroeconomic forces, [that are] much stronger than the current ongoing invasion in Ukraine," he said. Micael Johansson, CEO of Swedish defense giant Saab , meanwhile insisted the growth in European defense was "absolutely" a long-term trend. "I have a hard time seeing, after all that happened with the invasion in Ukraine and the aggressive neighbor that we have to the east … even if we get a ceasefire or peace deal that is reasonable with Ukraine, that [governments] would step back and say it's over," he said in an interview with CNBC toward the end of July. Earnings misses and downgrades The bull run this year hasn't been a continuously upward trajectory, even without questions surrounding the future of Ukraine. Shares of German arms manufacturer Rheinmetall shed 8% on Thursday, after the firm's earnings came in below expectations . The company said contracts had not been awarded during the reporting period given the election of a new government in Germany, but noted that an anticipated influx of orders in the second half of 2025 meant Rheinmetall was able to confirm its full-year guidance. Rheinmetall is one of the best performers in European defense this year, with its shares gaining roughly 160% over the course of 2025. In a Friday note, Deutsche Bank's Christoph Laskawi argued that Rheinmetall's second-quarter result "does not change the investment case by any means." "The order intake potential ahead remains significant and the win rate should be high which is the basis for sizeable revenue growth in the coming years," he said. Back in June , Citi's European Aerospace and Defence analyst Charles Armitage downgraded Hensoldt, Renk and Saab — whose shares have all more than doubled in value this year — to give them a "sell" rating. He argued at the time that the companies were "pricing in more growth than seems likely." A lot of optimism nevertheless still remains in the sector. "It's no surprise [defense] share prices have jumped sharply this year, maybe to unsustainable levels in the short term and a welcome resolution or ceasefire in Ukraine may see their prices soften," Neil Birrell, chief investment officer at U.K. investment management firm Premier Miton, told CNBC by email. "However, the spend on defence and related infrastructure is here to stay and will be taking place over the coming years and decades. The move to greater … regional self-reliance for defence, energy, food and raw materials is a very long-term one. Defence stocks will be big beneficiaries of that."
